search
Back to results

Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity

Primary Purpose

Atherosclerosis, Diet Modification, Serum; Disease

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cellulose (control)
Glycine
Alanine
Leucine
Isoleucine
Valine
Cysteine
Arginine
Methionine
Glutamate
Glutamine
Sponsored by
Rambam Health Care Campus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Atherosclerosis focused on measuring Amino acids, Macrophage atherogenicity, Triglycerides, Cholesterol, Lipoproteins

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy adult males between the ages of 18-50 after signing informed consent

Exclusion Criteria:

  • pregnancy, renal, pulmonary, cardiovascular or endocrinal diseases, diabetes, cancer, morbid obesity (body mass index, BMI > 40 kg/m2), heavy smoking (> 20 cigarettes/day), or consumption of more than two alcoholic drinks per day. Subjects from the same hospital unit or from the laboratory where this study is conducted are also excluded

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm 7

    Arm 8

    Arm 9

    Arm 10

    Arm 11

    Arm Type

    Sham Comparator

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    Control

    Glycine (Trade name: Glycine)

    Alanine (Trade name: L-Alanine)

    Leucine (Trade name: L-Leucine)

    Isoleucine (Trade name: L-Isoleucine)

    Valine (Trade name: L-Valine)

    Cysteine (Trade name: L-Cysteine)

    Arginine (Trade name: L-Arginine)

    Methionine (Trade name: DL-Methionine)

    Glutamate (Trade name: L-Glutamic acid)

    Glutamine (Trade name: L-Glutamine)

    Arm Description

    Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days

    Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.

    Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.

    Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.

    Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.

    Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.

    Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.

    Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.

    Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.

    Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.

    Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.

    Outcomes

    Primary Outcome Measures

    Serum atherogenicity
    Macrophage lipids (triglycerides and cholesterol) content (μg/mg cell protein) following incubation with serum derived from the subjects.

    Secondary Outcome Measures

    Serum triglyceride concentration
    Triglyceride concentration (mg/dL) vs control group
    Macrophage cholesterol content
    Cholesterol concentration (mg/dL) vs control group
    Serum oxidation
    Serum levels of thiobarbituric acid reactive substances (TBARS)

    Full Information

    First Posted
    May 25, 2017
    Last Updated
    June 7, 2017
    Sponsor
    Rambam Health Care Campus
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03180775
    Brief Title
    Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity
    Official Title
    Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 1, 2017 (Anticipated)
    Primary Completion Date
    December 15, 2017 (Anticipated)
    Study Completion Date
    May 1, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Rambam Health Care Campus

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Recently, the investigators have been screening for anti-atherogenic or pro-atherogenic amino acids (AAs) in the macrophage model system to better understand their role in atherogenesis. The findings so far suggest that specific AAs induce selective anti-atherogenic effects (glycine, alanine, leucine and cysteine) or pro-atherogenic effects (glutamate and glutamine) in macrophages. Taking together the above previous reports with the mechanisms behind macrophage foam cell formation and atherogenesis, it is possible that AAs could be anti-atherogenic or pro-atherogenic via their mechanism of action on macrophage foam cell formation. This paradigm may serve as a basis for the development of novel cardio-protective, anti-atherogenic nutritional, or therapeutic approaches, that should be studied in human trials.
    Detailed Description
    Atherosclerosis is the underlying cause of cardiovascular diseases (CVD), the major cause of death worldwide. Atherosclerosis is an inflammatory disease of the arteries in which activated macrophages are abundant in the atherosclerotic lesions. Macrophages play key roles during early atherogenesis. After differentiating from peripheral blood monocytes, the formed intimal macrophages take up oxidized/modified lipoproteins and are transformed into lipid-rich foam cells, the hallmark feature of early atherogenesis. In addition to lipoprotein uptake, lipid accumulation in macrophages can also result from alterations in cellular lipid metabolism, e.g. attenuated reverse lipid transport or enhanced rates of lipid biosynthesis. Although much progress has been made in understanding the role of different lipids (fatty acids, cholesterol, phospholipids or triglycerides) in macrophage foam-cell formation and atherosclerosis development, little is known about the potential impact of other nutrients, such as amino acids (AAs). Previous studies have demonstrated an association between specific AAs and increased CVD risk or higher prevalence of coronary artery disease (CAD). For instance, the role of the branched chain AAs (BCAAs; valine, leucine, and isoleucine) in atherogenesis and CVD has been recently studied. Association studies showed that the plasma levels of BCAAs significantly and independently correlated with dyslipidemia and CAD. However, BCAAs were found to possess cardio-protective effects in a heart failure rat model. Specifically, leucine was reported to attenuate atherosclerosis development in the atherosclerotic apoE-deficient (apoE-/-) mice model, by improving the plasma lipid profile and by reducing systemic inflammation. Other studies have indicated the ability of some AAs to exert anti-atherogenic effects. Glycine, the simplest AA, was inversely associated with the risk of acute myocardial infarction (AMI) in patients with high apolipoprotein B (apoB) and LDL-cholesterol levels. Cysteine is an essential AA in the biosynthesis of glutathione, a key endogenous anti-oxidant known for its anti-atherogenic properties in macrophage lipid metabolism leading to the attenuation of atherosclerosis development. Cysteine analogues such as N-acetyl cysteine (NAC) or ribose cysteine were shown to be anti-atherogenic. Arginine, a basic AA, is the main precursor for nitric oxide production in the vascular endothelium. Arginine was shown to protect endothelial cells from lipid peroxidation, and to delay or reduce atheroma formation. Arginine anti-atherogenicity includes its anti-oxidant properties and its ability to improve endothelial function in CVD or overweight patients. The aim of the proposed study is to investigate the effects of one month of supplementation with specific AAs on changes in the macrophage atherogenicity and lipid metabolism together with other risk markers of atherosclerosis development, such as serum oxidative status and lipid levels, on healthy subjects. Findings from the current proposed study may shed light on yet unknown mechanisms by which specific AAs affect atherosclerosis development and CVD risk and hence could possibly assist in the future development of anti-atherogenic strategies

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Atherosclerosis, Diet Modification, Serum; Disease
    Keywords
    Amino acids, Macrophage atherogenicity, Triglycerides, Cholesterol, Lipoproteins

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    110 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Control
    Arm Type
    Sham Comparator
    Arm Description
    Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
    Arm Title
    Glycine (Trade name: Glycine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
    Arm Title
    Alanine (Trade name: L-Alanine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
    Arm Title
    Leucine (Trade name: L-Leucine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
    Arm Title
    Isoleucine (Trade name: L-Isoleucine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
    Arm Title
    Valine (Trade name: L-Valine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
    Arm Title
    Cysteine (Trade name: L-Cysteine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
    Arm Title
    Arginine (Trade name: L-Arginine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
    Arm Title
    Methionine (Trade name: DL-Methionine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
    Arm Title
    Glutamate (Trade name: L-Glutamic acid)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
    Arm Title
    Glutamine (Trade name: L-Glutamine)
    Arm Type
    Experimental
    Arm Description
    Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
    Intervention Type
    Other
    Intervention Name(s)
    Cellulose (control)
    Intervention Description
    Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Glycine
    Other Intervention Name(s)
    Trade name: Glycine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Alanine
    Other Intervention Name(s)
    Trade name: L-Alanine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Leucine
    Other Intervention Name(s)
    Trade name: L-Leucine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Isoleucine
    Other Intervention Name(s)
    Trade name: L-Isoleucine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Valine
    Other Intervention Name(s)
    Trade name: L-Valine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Cysteine
    Other Intervention Name(s)
    Trade name: L-Cysteine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Arginine
    Other Intervention Name(s)
    Trade name: L-Arginine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Methionine
    Other Intervention Name(s)
    Trade name: DL-Methionine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Glutamate
    Other Intervention Name(s)
    Trade name: L-Glutamic acid (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Glutamine
    Other Intervention Name(s)
    Trade name: L-Glutamine (Manufacturer Fagron Inc)
    Intervention Description
    Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
    Primary Outcome Measure Information:
    Title
    Serum atherogenicity
    Description
    Macrophage lipids (triglycerides and cholesterol) content (μg/mg cell protein) following incubation with serum derived from the subjects.
    Time Frame
    1 year
    Secondary Outcome Measure Information:
    Title
    Serum triglyceride concentration
    Description
    Triglyceride concentration (mg/dL) vs control group
    Time Frame
    1 year
    Title
    Macrophage cholesterol content
    Description
    Cholesterol concentration (mg/dL) vs control group
    Time Frame
    1 year
    Title
    Serum oxidation
    Description
    Serum levels of thiobarbituric acid reactive substances (TBARS)
    Time Frame
    1 year

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: healthy adult males between the ages of 18-50 after signing informed consent Exclusion Criteria: pregnancy, renal, pulmonary, cardiovascular or endocrinal diseases, diabetes, cancer, morbid obesity (body mass index, BMI > 40 kg/m2), heavy smoking (> 20 cigarettes/day), or consumption of more than two alcoholic drinks per day. Subjects from the same hospital unit or from the laboratory where this study is conducted are also excluded
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Claudia Grajeda Iglesias, PhD
    Phone
    972-4-8295278
    Email
    claugrajeda@technion.ac.il
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Tony Hayek, Prof
    Organizational Affiliation
    Rambam Health Care Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    24727233
    Citation
    Michas G, Micha R, Zampelas A. Dietary fats and cardiovascular disease: putting together the pieces of a complicated puzzle. Atherosclerosis. 2014 Jun;234(2):320-8. doi: 10.1016/j.atherosclerosis.2014.03.013. Epub 2014 Mar 27.
    Results Reference
    background
    PubMed Identifier
    18650503
    Citation
    Dickhout JG, Basseri S, Austin RC. Macrophage function and its impact on atherosclerotic lesion composition, progression, and stability: the good, the bad, and the ugly. Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1413-5. doi: 10.1161/ATVBAHA.108.169144. No abstract available.
    Results Reference
    background
    PubMed Identifier
    26959710
    Citation
    Rom O, Aviram M. Endogenous or exogenous antioxidants vs. pro-oxidants in macrophage atherogenicity. Curr Opin Lipidol. 2016 Apr;27(2):204-6. doi: 10.1097/MOL.0000000000000287. No abstract available.
    Results Reference
    background
    PubMed Identifier
    24445035
    Citation
    Afonso Mda S, Castilho G, Lavrador MS, Passarelli M, Nakandakare ER, Lottenberg SA, Lottenberg AM. The impact of dietary fatty acids on macrophage cholesterol homeostasis. J Nutr Biochem. 2014 Feb;25(2):95-103. doi: 10.1016/j.jnutbio.2013.10.001. Epub 2013 Oct 31.
    Results Reference
    background
    PubMed Identifier
    21502372
    Citation
    Huang Y, Zhou M, Sun H, Wang Y. Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? Cardiovasc Res. 2011 May 1;90(2):220-3. doi: 10.1093/cvr/cvr070.
    Results Reference
    background
    PubMed Identifier
    26231617
    Citation
    Yang RY, Wang SM, Sun L, Liu JM, Li HX, Sui XF, Wang M, Xiu HL, Wang S, He Q, Dong J, Chen WX. Association of branched-chain amino acids with coronary artery disease: A matched-pair case-control study. Nutr Metab Cardiovasc Dis. 2015 Oct;25(10):937-42. doi: 10.1016/j.numecd.2015.06.003. Epub 2015 Jun 14.
    Results Reference
    background
    PubMed Identifier
    20173117
    Citation
    Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, Dungan J, Newby LK, Hauser ER, Ginsburg GS, Newgard CB, Kraus WE. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010 Apr;3(2):207-14. doi: 10.1161/CIRCGENETICS.109.852814. Epub 2010 Feb 19.
    Results Reference
    background
    PubMed Identifier
    24401236
    Citation
    Bhattacharya S, Granger CB, Craig D, Haynes C, Bain J, Stevens RD, Hauser ER, Newgard CB, Kraus WE, Newby LK, Shah SH. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis. 2014 Jan;232(1):191-6. doi: 10.1016/j.atherosclerosis.2013.10.036. Epub 2013 Nov 12.
    Results Reference
    background
    PubMed Identifier
    26141987
    Citation
    Tanada Y, Shioi T, Kato T, Kawamoto A, Okuda J, Kimura T. Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci. 2015 Sep 15;137:20-7. doi: 10.1016/j.lfs.2015.06.021. Epub 2015 Jul 2.
    Results Reference
    background
    PubMed Identifier
    26687933
    Citation
    Zhao Y, Dai XY, Zhou Z, Zhao GX, Wang X, Xu MJ. Leucine supplementation via drinking water reduces atherosclerotic lesions in apoE null mice. Acta Pharmacol Sin. 2016 Feb;37(2):196-203. doi: 10.1038/aps.2015.88. Epub 2015 Dec 21.
    Results Reference
    background
    PubMed Identifier
    22450427
    Citation
    Wurtz P, Raiko JR, Magnussen CG, Soininen P, Kangas AJ, Tynkkynen T, Thomson R, Laatikainen R, Savolainen MJ, Laurikka J, Kuukasjarvi P, Tarkka M, Karhunen PJ, Jula A, Viikari JS, Kahonen M, Lehtimaki T, Juonala M, Ala-Korpela M, Raitakari OT. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J. 2012 Sep;33(18):2307-16. doi: 10.1093/eurheartj/ehs020. Epub 2012 Mar 26.
    Results Reference
    background
    PubMed Identifier
    26647293
    Citation
    Selhub J, Troen AM. Sulfur amino acids and atherosclerosis: a role for excess dietary methionine. Ann N Y Acad Sci. 2016 Jan;1363:18-25. doi: 10.1111/nyas.12962. Epub 2015 Dec 8.
    Results Reference
    background
    PubMed Identifier
    7661880
    Citation
    Toborek M, Kopieczna-Grzebieniak E, Drozdz M, Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis. 1995 Jun;115(2):217-24. doi: 10.1016/0021-9150(94)05516-l.
    Results Reference
    background
    PubMed Identifier
    23754667
    Citation
    Julve J, Escola-Gil JC, Rodriguez-Millan E, Martin-Campos JM, Jauhiainen M, Quesada H, Renteria-Obregon IM, Osada J, Sanchez-Quesada JL, Blanco-Vaca F. Methionine-induced hyperhomocysteinemia impairs the antioxidant ability of high-density lipoproteins without reducing in vivo macrophage-specific reverse cholesterol transport. Mol Nutr Food Res. 2013 Oct;57(10):1814-24. doi: 10.1002/mnfr.201300133. Epub 2013 Jun 10.
    Results Reference
    background
    PubMed Identifier
    26606905
    Citation
    Yang AN, Zhang HP, Sun Y, Yang XL, Wang N, Zhu G, Zhang H, Xu H, Ma SC, Zhang Y, Li GZ, Jia YX, Cao J, Jiang YD. High-methionine diets accelerate atherosclerosis by HHcy-mediated FABP4 gene demethylation pathway via DNMT1 in ApoE(-/-) mice. FEBS Lett. 2015 Dec 21;589(24 Pt B):3998-4009. doi: 10.1016/j.febslet.2015.11.010. Epub 2015 Nov 26.
    Results Reference
    background
    PubMed Identifier
    26722126
    Citation
    Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, Nygard OK. Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable Angina Pectoris. J Am Heart Assoc. 2015 Dec 31;5(1):e002621. doi: 10.1161/JAHA.115.002621.
    Results Reference
    background
    PubMed Identifier
    17588583
    Citation
    Rosenblat M, Volkova N, Coleman R, Aviram M. Anti-oxidant and anti-atherogenic properties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice. Atherosclerosis. 2007 Dec;195(2):e61-8. doi: 10.1016/j.atherosclerosis.2007.05.012. Epub 2007 Jun 22.
    Results Reference
    background
    PubMed Identifier
    25463112
    Citation
    Kader T, Porteous CM, Williams MJ, Gieseg SP, McCormick SP. Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. Atherosclerosis. 2014 Dec;237(2):725-33. doi: 10.1016/j.atherosclerosis.2014.10.101. Epub 2014 Nov 1.
    Results Reference
    background
    PubMed Identifier
    12742995
    Citation
    Suschek CV, Schnorr O, Hemmrich K, Aust O, Klotz LO, Sies H, Kolb-Bachofen V. Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14. doi: 10.1161/01.CIR.0000066909.13953.F1. Epub 2003 May 12.
    Results Reference
    background
    PubMed Identifier
    10069793
    Citation
    Wang BY, Ho HK, Lin PS, Schwarzacher SP, Pollman MJ, Gibbons GH, Tsao PS, Cooke JP. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation. 1999 Mar 9;99(9):1236-41. doi: 10.1161/01.cir.99.9.1236.
    Results Reference
    background
    PubMed Identifier
    27281800
    Citation
    Deveaux A, Pham I, West SG, Andre E, Lantoine-Adam F, Bunouf P, Sadi S, Hermier D, Mathe V, Fouillet H, Huneau JF, Benamouzig R, Mariotti F. l-Arginine Supplementation Alleviates Postprandial Endothelial Dysfunction When Baseline Fasting Plasma Arginine Concentration Is Low: A Randomized Controlled Trial in Healthy Overweight Adults with Cardiometabolic Risk Factors. J Nutr. 2016 Jul;146(7):1330-40. doi: 10.3945/jn.115.227959. Epub 2016 Jun 8.
    Results Reference
    background
    PubMed Identifier
    28431321
    Citation
    Rom O, Grajeda-Iglesias C, Najjar M, Abu-Saleh N, Volkova N, Dar DE, Hayek T, Aviram M. Atherogenicity of amino acids in the lipid-laden macrophage model system in vitro and in atherosclerotic mice: a key role for triglyceride metabolism. J Nutr Biochem. 2017 Jul;45:24-38. doi: 10.1016/j.jnutbio.2017.02.023. Epub 2017 Apr 6.
    Results Reference
    background
    PubMed Identifier
    2784145
    Citation
    Eierman DF, Johnson CE, Haskill JS. Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. J Immunol. 1989 Mar 15;142(6):1970-6.
    Results Reference
    background
    PubMed Identifier
    17364057
    Citation
    Nikitina NA, Sobenin IA, Myasoedova VA, Korennaya VV, Mel'nichenko AA, Khalilov EM, Orekhov AN. Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull Exp Biol Med. 2006 Jun;141(6):712-5. doi: 10.1007/s10517-006-0260-7. English, Russian.
    Results Reference
    result
    PubMed Identifier
    24401239
    Citation
    Hamoud S, Hayek T, Volkova N, Attias J, Moscoviz D, Rosenblat M, Aviram M. Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study. Atherosclerosis. 2014 Jan;232(1):204-10. doi: 10.1016/j.atherosclerosis.2013.11.037. Epub 2013 Nov 19.
    Results Reference
    result
    PubMed Identifier
    12449285
    Citation
    Trumbo P, Schlicker S, Yates AA, Poos M; Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002 Nov;102(11):1621-30. doi: 10.1016/s0002-8223(02)90346-9. No abstract available. Erratum In: J Am Diet Assoc. 2003 May;103(5):563.
    Results Reference
    result

    Learn more about this trial

    Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity

    We'll reach out to this number within 24 hrs